The US Food and Drug Administration has approved VYALEV, a groundbreaking therapy developed by AbbVie to treat adults with ...

AbbVie announced that the US Food and Drug Administration (FDA) has approved Vyalev (foscarbidopa and foslevodopa) as the first and only subcutaneous 24-hour infusion of levodopa-based therapy for the ...

Here's a recap of the week’s most important stories.

The first levodopa-based treatment for motor fluctuations in people with advanced Parkinson's disease, VYALEVa subcutaneous ...

Vyalev (AbbVie) is the first and only subcutaneous 24-hour continuous infusion of levodopa-based therapy to address motor fluctuations in advanced Parkinson’s disease.

After a couple of negative decisions, the US Food and Drug Administration (FDA) has approved Vyalev (foscarbidopa and ...

AbbVie has finally claimed FDA approval for its advanced Parkinson's disease therapy Vyalev, 18 months after the US regulator ...

Vyalev (foscarbidopa and foslevodopa) as the first and only subcutaneous 24-hour infusion of levodopa-based therapy for motor ...

AbbVie also sells a continuous-delivery system for Parkinson's branded as Duopa that pumps a levodopa-carbidopa gel directly ...

Vyalev’s clearance is the second victory for AbbVie in Parkinson’s this year, following an April readout for a drug acquired through its Cerevel buyout.

AbbVie made history in 2015 with its Parkinson’s disease infusion pump therapy Duopa, kicking off a trend of delivery system ...

(RTTNews) - AbbVie Inc. (ABBV) Thursday said that the U.S. Food and Drug Administration (FDA) has approved Vyalev for the treatment of motor fluctuations in adults with advanced Parkinson's disease ...